Laser Therapy Vs Surgery For Temporal Lobe Epilepsy

What was studied

This paper describes the plan for a clinical trial, not results. The trial will study adults with drug-resistant temporal lobe epilepsy who have completed a comprehensive presurgical evaluation and are considered suitable for surgical treatment at participating centres.

Participants will be randomly assigned to 1 of 2 treatments: magnetic resonance-guided laser interstitial thermal therapy (MRgLITT), a minimally invasive laser procedure, or open surgery for mesial temporal lobe epilepsy. The study is designed so the patients and treating teams know which treatment was given, but the people judging outcomes and analyzing the data will not know.

What they found

No study results are reported yet because this is a trial protocol. The main planned outcome is the seizure-free rate 12 months after surgery, defined as ILAE Class 1. The trial will also measure seizure outcomes including seizure frequency and severity, memory and thinking, safety outcomes, hospital stay, repeat surgery, antiseizure medicine reduction, quality of life, and healthcare use and economic outcomes.

Limits of the evidence

Because this is only the study plan, it cannot show whether one treatment works better or is safer yet. The trial includes adults who are already judged to be suitable candidates for surgical treatment, so the findings may not apply to children or to people who are not eligible for surgery. The study is open-label, meaning patients and treating teams know which procedure was done, which could affect some reported outcomes, although the outcome assessors and statistical analysts will be blinded.

For families and caregivers

For families, this study matters because it aims to compare a less invasive laser treatment with open epilepsy surgery in a randomized way. If completed, it could provide better evidence about whether the laser approach has similar seizure outcomes and how the two options compare for memory, recovery, side effects, and hospital stay. Right now, it does not change care by itself because no outcomes are available yet.

What to watch next

Stronger evidence will come when the trial reports its 12-month seizure, safety, and cognitive results, and families can ask a clinician how these options compare for a specific surgical candidate.

Terms in this summary

mesial temporal lobe epilepsy

A type of epilepsy that starts in deep structures of the temporal lobe and is often difficult to control with medicine.

drug-resistant

Seizures continue despite appropriate antiseizure medicine treatment.

MRgLITT

A minimally invasive procedure that uses a laser, guided by MRI, to heat and destroy a small area of brain tissue linked to seizures.

open surgery

A standard operation used to remove or target brain tissue involved in causing seizures.

randomised

Assigned by chance to one treatment group or another.

blinded-endpoint

The people judging the study outcomes do not know which treatment each person received.

non-inferiority study

A study designed to test whether a new treatment is not unacceptably worse than the standard treatment.

ILAE Class 1

A seizure outcome category meaning seizure-free after treatment.